- Net Income: Zhifei Biological reported a fiscal year net income of 8.07 billion yuan.
- Income vs Estimates: This figure fell short of the estimated 8.99 billion yuan.
- Revenue: The company’s revenue stood at 52.92 billion yuan.
- Revenue vs Estimates: It was more than the estimated revenue of 49.44 billion yuan.
- Investor Ratings: Zhifei Biological received 26 buy ratings, a single hold rating, and no sell ratings.
A look at Chongqing Zhifei Biological Products Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 3 | |
| Growth | 5 | |
| Resilience | 3 | |
| Momentum | 3 | |
| OVERALL SMART SCORE | 3.2 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Analysts have highlighted a positive long-term outlook for Chongqing Zhifei Biological Products Company Ltd. based on its Smartkarma Smart Scores. With a high growth score of 5, the company is expected to experience strong expansion in the coming years. This is supported by its solid momentum score of 3, indicating that it is well-positioned for continued growth in the market. Additionally, the company has a respectable dividend score of 3, suggesting it may provide steady returns to investors over time.
Despite the average value score of 2, the company’s resilience score of 3 indicates its ability to weather challenging market conditions. Overall, Chongqing Zhifei Biological Products is recognized for its research, manufacture, and sale of vaccines and biological products, aligning with its commitment to delivering prevention products, blood products, diagnostic reagents, and therapeutic agents to the market.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
